koonkoon personal page - To The Moon

koonkoon

koonkoon

No personal profile

792Follow

127Followers

0Topic

0Badge

2023-05-09

$Chembio Diagnostics(CEMI)$ iinside balancr money how ,if delisting

2022-05-28

ok

@CyrilDavy:3 best travel stocks to buy as the industry rebounds

2022-03-11

$DiDi Global Inc.(DIDI)$ddie drop like waterfall

2022-02-02

good

@SlowIncome:(20/09)Today's pre-market GAINERS:$Zivo Bioscience, Inc.(ZIVO)$$Stellar Biotechnologies(EDSA)$$Verastem(VSTM)$$LAVA Therapeutics N.V.(LVTX)$$Synlogic, Inc.(SYBX)$Please like and follow for daily updates

2022-01-29

$DiDi Global Inc.(DIDI)$ddrop until no value

2022-01-27

$DiDi Global Inc.(DIDI)$nno hope waiting die

2022-01-20

drop

@GenieLim:$Chembio Diagnostics(CEMI)$ diagnostic kits doubled in price and are in shortage, further exacerbated by biden policies and insurers are tied up gobbling supplies!$10 in time!

2021-09-15

Wow

@妞大福:$Agile Therapeutics, Inc.(AGRX)$[微笑] [微笑]

2021-09-14

$EVERGRANDE(03333)$die

2021-09-11

same

@Zna:$Clover Health Corp(CLOV)$Walao

2021-09-09

tiger ask close

@jayden1013:$GTT Communications, Inc.(GTTN)$How your all thinking about this ，sell off before 28th Sept??

2021-09-09

same regret

@MMMMMMMMMMM5:$Globalstar(GSAT)$Only regret is selling off a 2.07 so early…

2021-09-08

Wow

@Daweeew:$Rocket Lab USA, Inc.(RKLB)$新西蘭本地招聘網站上，Rocket Lab 招聘崗位高達46個。而且平均年薪都高於市場價。有互聯網公司那味道了。年報回調後，繼續加碼。

2021-09-03

same

@鑫鑫向荣吧:$GTT Communications, Inc.(GTTN)$如何是好?

2021-08-30

$SEMBCORP MARINE LTD(S51.SI)$up

2021-08-30

$SEMBCORP MARINE LTD(S51.SI)$buybuy

2021-08-25

Too deep

Sorry, the original content has been removed

2021-08-19

$DiDi Global Inc.(DIDI)$ssad eveeyday non stop drop

2021-08-17

$Tonix Pharmaceuticals(TNXP)$hhold

2021-08-17

$GTT Communications, Inc.(GTTN)$bburn money

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3564546889826365","uuid":"3564546889826365","gmtCreate":1601452866902,"gmtModify":1706620737114,"name":"koonkoon","pinyin":"koonkoon","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":127,"headSize":792,"tweetSize":410,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.18%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.07","exceedPercentage":"93.24%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9947728187,"gmtCreate":1683631817450,"gmtModify":1683631821576,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CEMI\">$Chembio Diagnostics(CEMI)$ &nbsp;</a>iinside balancr money how ,if delisting","listText":"<a href=\"https://ttm.financial/S/CEMI\">$Chembio Diagnostics(CEMI)$ &nbsp;</a>iinside balancr money how ,if delisting","text":"$Chembio Diagnostics(CEMI)$ iinside balancr money how ,if delisting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947728187","isVote":1,"tweetType":1,"viewCount":447,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9025664167,"gmtCreate":1653688983159,"gmtModify":1676535325498,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9025664167","repostId":"9089221197","repostType":1,"repost":{"id":9089221197,"gmtCreate":1649995737382,"gmtModify":1676534625922,"author":{"id":"9000000000000641","authorId":"9000000000000641","name":"CyrilDavy","avatar":"https://static.tigerbbs.com/fd67ba4a6ca5ca66b27af6afcce989dc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"9000000000000641","authorIdStr":"9000000000000641"},"themes":[],"title":"3 best travel stocks to buy as the industry rebounds","htmlText":"Delta Airlines CEO said that the industry was making a comeback. Travel stocks are expected to benefit during this rebound. Airbnb, TripAdvisor, and Booking offer the best returns. The global travel industry is rebounding as countries reopen their borders and ease restrictions. In a statement on Wednesday, Delta’s CEO said that the company has never seen such demand. This explains why travel companies have done well recently. The ETFMG Travel Tech ETF (AWAY) has risen by 20% from its YTD low. Here are some of the best travel stocks to invest in. Airbnb Airbnb<a href=\"https://laohu8.com/S/ABNB\">$Airbnb, Inc.(ABNB)$</a>&nbsp;is a leading company that provides on-demand vacation rentals services. With a market cap of over $109 billion, the firm is more valuable than Hilton, Marriott, and Wynd","listText":"Delta Airlines CEO said that the industry was making a comeback. Travel stocks are expected to benefit during this rebound. Airbnb, TripAdvisor, and Booking offer the best returns. The global travel industry is rebounding as countries reopen their borders and ease restrictions. In a statement on Wednesday, Delta’s CEO said that the company has never seen such demand. This explains why travel companies have done well recently. The ETFMG Travel Tech ETF (AWAY) has risen by 20% from its YTD low. Here are some of the best travel stocks to invest in. Airbnb Airbnb<a href=\"https://laohu8.com/S/ABNB\">$Airbnb, Inc.(ABNB)$</a>&nbsp;is a leading company that provides on-demand vacation rentals services. With a market cap of over $109 billion, the firm is more valuable than Hilton, Marriott, and Wynd","text":"Delta Airlines CEO said that the industry was making a comeback. Travel stocks are expected to benefit during this rebound. Airbnb, TripAdvisor, and Booking offer the best returns. The global travel industry is rebounding as countries reopen their borders and ease restrictions. In a statement on Wednesday, Delta’s CEO said that the company has never seen such demand. This explains why travel companies have done well recently. The ETFMG Travel Tech ETF (AWAY) has risen by 20% from its YTD low. Here are some of the best travel stocks to invest in. Airbnb Airbnb$Airbnb, Inc.(ABNB)$ is a leading company that provides on-demand vacation rentals services. With a market cap of over $109 billion, the firm is more valuable than Hilton, Marriott, and Wynd","images":[{"img":"https://community-static.tradeup.com/news/5afee681cc917aefacca9aca04d6b1c6","width":"-1","height":"-1"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9089221197","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":474,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9036359884,"gmtCreate":1646996487894,"gmtModify":1676534185585,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/DIDI\">$DiDi Global Inc.(DIDI)$</a>ddie drop like waterfall","listText":"<a href=\"https://ttm.financial/S/DIDI\">$DiDi Global Inc.(DIDI)$</a>ddie drop like waterfall","text":"$DiDi Global Inc.(DIDI)$ddie drop like waterfall","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":14,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9036359884","isVote":1,"tweetType":1,"viewCount":1018,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091126120,"gmtCreate":1643810511360,"gmtModify":1676533858535,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":14,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091126120","repostId":"860103463","repostType":1,"repost":{"id":860103463,"gmtCreate":1632142934652,"gmtModify":1676530709270,"author":{"id":"3586061751257522","authorId":"3586061751257522","name":"SlowIncome","avatar":"https://static.tigerbbs.com/8f58da85f59ba0a3ddf93647be45c630","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586061751257522","authorIdStr":"3586061751257522"},"themes":[],"htmlText":"(20/09)Today's pre-market GAINERS:<a href=\"https://laohu8.com/S/ZIVO\">$Zivo Bioscience, Inc.(ZIVO)$</a><a href=\"https://laohu8.com/S/EDSA\">$Stellar Biotechnologies(EDSA)$</a><a href=\"https://laohu8.com/S/VSTM\">$Verastem(VSTM)$</a><a href=\"https://laohu8.com/S/LVTX\">$LAVA Therapeutics N.V.(LVTX)$</a><a href=\"https://laohu8.com/S/SYBX\">$Synlogic, Inc.(SYBX)$</a>Please like and follow for daily updates&nbsp;","listText":"(20/09)Today's pre-market GAINERS:<a href=\"https://laohu8.com/S/ZIVO\">$Zivo Bioscience, Inc.(ZIVO)$</a><a href=\"https://laohu8.com/S/EDSA\">$Stellar Biotechnologies(EDSA)$</a><a href=\"https://laohu8.com/S/VSTM\">$Verastem(VSTM)$</a><a href=\"https://laohu8.com/S/LVTX\">$LAVA Therapeutics N.V.(LVTX)$</a><a href=\"https://laohu8.com/S/SYBX\">$Synlogic, Inc.(SYBX)$</a>Please like and follow for daily updates&nbsp;","text":"(20/09)Today's pre-market GAINERS:$Zivo Bioscience, Inc.(ZIVO)$$Stellar Biotechnologies(EDSA)$$Verastem(VSTM)$$LAVA Therapeutics N.V.(LVTX)$$Synlogic, Inc.(SYBX)$Please like and follow for daily updates","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860103463","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":737,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9099575983,"gmtCreate":1643400522440,"gmtModify":1676533816026,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/DIDI\">$DiDi Global Inc.(DIDI)$</a>ddrop until no value","listText":"<a href=\"https://ttm.financial/S/DIDI\">$DiDi Global Inc.(DIDI)$</a>ddrop until no value","text":"$DiDi Global Inc.(DIDI)$ddrop until no value","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":17,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9099575983","isVote":1,"tweetType":1,"viewCount":1043,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9099367132,"gmtCreate":1643297690041,"gmtModify":1676533800451,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/DIDI\">$DiDi Global Inc.(DIDI)$</a>nno hope waiting die","listText":"<a href=\"https://ttm.financial/S/DIDI\">$DiDi Global Inc.(DIDI)$</a>nno hope waiting die","text":"$DiDi Global Inc.(DIDI)$nno hope waiting die","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9099367132","isVote":1,"tweetType":1,"viewCount":894,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9004261443,"gmtCreate":1642618878182,"gmtModify":1676533727835,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"drop","listText":"drop","text":"drop","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004261443","repostId":"697531999","repostType":1,"repost":{"id":697531999,"gmtCreate":1642513964040,"gmtModify":1676532598935,"author":{"id":"3555507855053297","authorId":"3555507855053297","name":"GenieLim","avatar":"https://static.tigerbbs.com/5bcad8d407a08ee1a7a78539043d2eb3","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3555507855053297","authorIdStr":"3555507855053297"},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/CEMI\">$Chembio Diagnostics(CEMI)$</a> diagnostic kits doubled in price and are in shortage, further exacerbated by biden policies and insurers are tied up gobbling supplies!$10 in time!","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/CEMI\">$Chembio Diagnostics(CEMI)$</a> diagnostic kits doubled in price and are in shortage, further exacerbated by biden policies and insurers are tied up gobbling supplies!$10 in time!","text":"$Chembio Diagnostics(CEMI)$ diagnostic kits doubled in price and are in shortage, further exacerbated by biden policies and insurers are tied up gobbling supplies!$10 in time!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/697531999","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":668,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":882850615,"gmtCreate":1631676855037,"gmtModify":1676530606552,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/882850615","repostId":"385947109","repostType":1,"repost":{"id":385947109,"gmtCreate":1613497874801,"gmtModify":1704881340465,"author":{"id":"3549945745640020","authorId":"3549945745640020","name":"妞大福","avatar":"https://static.tigerbbs.com/fe05f7d36b73c35cc98c0e813c101494","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3549945745640020","authorIdStr":"3549945745640020"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AGRX\">$Agile Therapeutics, Inc.(AGRX)$</a>[微笑]&nbsp;[微笑]&nbsp;","listText":"<a href=\"https://laohu8.com/S/AGRX\">$Agile Therapeutics, Inc.(AGRX)$</a>[微笑]&nbsp;[微笑]&nbsp;","text":"$Agile Therapeutics, Inc.(AGRX)$[微笑] [微笑]","images":[{"img":"https://static.tigerbbs.com/22a32f5285665ad7e37c9fb804b35f53","width":"1170","height":"2026"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/385947109","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":313,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886505493,"gmtCreate":1631601960012,"gmtModify":1676530586921,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/03333\">$EVERGRANDE(03333)$</a>die","listText":"<a href=\"https://laohu8.com/S/03333\">$EVERGRANDE(03333)$</a>die","text":"$EVERGRANDE(03333)$die","images":[{"img":"https://static.tigerbbs.com/012ce46522642ce736cf85b6184674dd","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/886505493","isVote":1,"tweetType":1,"viewCount":548,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":881103389,"gmtCreate":1631313163641,"gmtModify":1676530524578,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"same","listText":"same","text":"same","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/881103389","repostId":"881979952","repostType":1,"repost":{"id":881979952,"gmtCreate":1631287831776,"gmtModify":1676530521799,"author":{"id":"3575694741352376","authorId":"3575694741352376","name":"Zna","avatar":"https://static.tigerbbs.com/f63bd92e1888ac82cee4b68bed642662","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575694741352376","authorIdStr":"3575694741352376"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CLOV\">$Clover Health Corp(CLOV)$</a>Walao","listText":"<a href=\"https://laohu8.com/S/CLOV\">$Clover Health Corp(CLOV)$</a>Walao","text":"$Clover Health Corp(CLOV)$Walao","images":[{"img":"https://static.tigerbbs.com/dd5dae88219e09fe3f32309305bd8ce8","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/881979952","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883929247,"gmtCreate":1631197221289,"gmtModify":1676530494299,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"tiger ask close","listText":"tiger ask close","text":"tiger ask close","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883929247","repostId":"889092154","repostType":1,"repost":{"id":889092154,"gmtCreate":1631089062078,"gmtModify":1676530464523,"author":{"id":"3574861109643087","authorId":"3574861109643087","name":"jayden1013","avatar":"https://static.tigerbbs.com/7eb4202e5bd8674e8ebcac5e64c14817","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574861109643087","authorIdStr":"3574861109643087"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GTTN\">$GTT Communications, Inc.(GTTN)$</a><a href=\"https://laohu8.com/S/GTTN\"></a>How your all thinking about this ，sell off before 28th Sept??","listText":"<a href=\"https://laohu8.com/S/GTTN\">$GTT Communications, Inc.(GTTN)$</a><a href=\"https://laohu8.com/S/GTTN\"></a>How your all thinking about this ，sell off before 28th Sept??","text":"$GTT Communications, Inc.(GTTN)$How your all thinking about this ，sell off before 28th Sept??","images":[{"img":"https://static.tigerbbs.com/c089209a69d61decedd2bc34594d0c35","width":"1080","height":"2412"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/889092154","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":273,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889410618,"gmtCreate":1631167798634,"gmtModify":1676530485572,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"same regret","listText":"same regret","text":"same regret","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/889410618","repostId":"889246710","repostType":1,"repost":{"id":889246710,"gmtCreate":1631153750130,"gmtModify":1676530481797,"author":{"id":"3577004405895578","authorId":"3577004405895578","name":"MMMMMMMMMMM5","avatar":"https://community-static.tradeup.com/news/569363eac18cab5a240c47cedf304bd3","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3577004405895578","authorIdStr":"3577004405895578"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GSAT\">$Globalstar(GSAT)$</a>Only regret is selling off a 2.07 so early…","listText":"<a href=\"https://laohu8.com/S/GSAT\">$Globalstar(GSAT)$</a>Only regret is selling off a 2.07 so early…","text":"$Globalstar(GSAT)$Only regret is selling off a 2.07 so early…","images":[{"img":"https://static.tigerbbs.com/218d6edd4993aca76322a335a06e44c8","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/889246710","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":185,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880234598,"gmtCreate":1631059400714,"gmtModify":1676530454064,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/880234598","repostId":"880871835","repostType":1,"repost":{"id":880871835,"gmtCreate":1631048934127,"gmtModify":1676530450396,"author":{"id":"3576314933460541","authorId":"3576314933460541","name":"Daweeew","avatar":"https://static.tigerbbs.com/59cbea7ef4ac416e4f6778862f832c8f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576314933460541","authorIdStr":"3576314933460541"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RKLB\">$Rocket Lab USA, Inc.(RKLB)$</a>新西蘭本地招聘網站上，Rocket Lab 招聘崗位高達46個。而且平均年薪都高於市場價。有互聯網公司那味道了。年報回調後，繼續加碼。","listText":"<a href=\"https://laohu8.com/S/RKLB\">$Rocket Lab USA, Inc.(RKLB)$</a>新西蘭本地招聘網站上，Rocket Lab 招聘崗位高達46個。而且平均年薪都高於市場價。有互聯網公司那味道了。年報回調後，繼續加碼。","text":"$Rocket Lab USA, Inc.(RKLB)$新西蘭本地招聘網站上，Rocket Lab 招聘崗位高達46個。而且平均年薪都高於市場價。有互聯網公司那味道了。年報回調後，繼續加碼。","images":[{"img":"https://static.tigerbbs.com/0701f5d23bfa5826f2f5fc70aea6d487","width":"828","height":"1792"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/880871835","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815691521,"gmtCreate":1630672976263,"gmtModify":1676530372291,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"same","listText":"same","text":"same","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815691521","repostId":"812412921","repostType":1,"repost":{"id":812412921,"gmtCreate":1630601896563,"gmtModify":1676530354543,"author":{"id":"3571724125342289","authorId":"3571724125342289","name":"鑫鑫向荣吧","avatar":"https://static.tigerbbs.com/7ac0a9ef9307b3f482f9dc4e5ab3d891","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571724125342289","authorIdStr":"3571724125342289"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GTTN\">$GTT Communications, Inc.(GTTN)$</a>如何是好?","listText":"<a href=\"https://laohu8.com/S/GTTN\">$GTT Communications, Inc.(GTTN)$</a>如何是好?","text":"$GTT Communications, Inc.(GTTN)$如何是好?","images":[{"img":"https://static.tigerbbs.com/57377fcd7a856f97286076f994673aa5","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/812412921","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811339056,"gmtCreate":1630288360175,"gmtModify":1676530257681,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/S51.SI\">$SEMBCORP MARINE LTD(S51.SI)$</a>up","listText":"<a href=\"https://laohu8.com/S/S51.SI\">$SEMBCORP MARINE LTD(S51.SI)$</a>up","text":"$SEMBCORP MARINE LTD(S51.SI)$up","images":[{"img":"https://static.tigerbbs.com/470522b5d856be31331019dda2424171","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/811339056","isVote":1,"tweetType":1,"viewCount":408,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575290973507485","authorId":"3575290973507485","name":"Rookie22","avatar":"https://static.tigerbbs.com/c6852efd5f87d9ecf7965e213c38ac97","crmLevel":4,"crmLevelSwitch":1,"idStr":"3575290973507485","authorIdStr":"3575290973507485"},"content":"Good luck","text":"Good luck","html":"Good luck"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":811330091,"gmtCreate":1630288320813,"gmtModify":1676530257657,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/S51.SI\">$SEMBCORP MARINE LTD(S51.SI)$</a>buybuy","listText":"<a href=\"https://laohu8.com/S/S51.SI\">$SEMBCORP MARINE LTD(S51.SI)$</a>buybuy","text":"$SEMBCORP MARINE LTD(S51.SI)$buybuy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811330091","isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":837616092,"gmtCreate":1629882565116,"gmtModify":1676530161263,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"Too deep","listText":"Too deep","text":"Too deep","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/837616092","repostId":"838857096","repostType":1,"isVote":1,"tweetType":1,"viewCount":150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":838833294,"gmtCreate":1629384305418,"gmtModify":1676530024414,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DIDI\">$DiDi Global Inc.(DIDI)$</a>ssad eveeyday non stop drop&nbsp;","listText":"<a href=\"https://laohu8.com/S/DIDI\">$DiDi Global Inc.(DIDI)$</a>ssad eveeyday non stop drop&nbsp;","text":"$DiDi Global Inc.(DIDI)$ssad eveeyday non stop drop","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/838833294","isVote":1,"tweetType":1,"viewCount":305,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":833961805,"gmtCreate":1629198169207,"gmtModify":1676529962796,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$</a>hhold","listText":"<a href=\"https://laohu8.com/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$</a>hhold","text":"$Tonix Pharmaceuticals(TNXP)$hhold","images":[{"img":"https://static.tigerbbs.com/2b660d784070924d502e6b573647808d","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/833961805","isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":833963328,"gmtCreate":1629198099964,"gmtModify":1676529962759,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GTTN\">$GTT Communications, Inc.(GTTN)$</a>bburn money","listText":"<a href=\"https://laohu8.com/S/GTTN\">$GTT Communications, Inc.(GTTN)$</a>bburn money","text":"$GTT Communications, Inc.(GTTN)$bburn money","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/833963328","isVote":1,"tweetType":1,"viewCount":149,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9947728187,"gmtCreate":1683631817450,"gmtModify":1683631821576,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CEMI\">$Chembio Diagnostics(CEMI)$ &nbsp;</a>iinside balancr money how ,if delisting","listText":"<a href=\"https://ttm.financial/S/CEMI\">$Chembio Diagnostics(CEMI)$ &nbsp;</a>iinside balancr money how ,if delisting","text":"$Chembio Diagnostics(CEMI)$ iinside balancr money how ,if delisting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947728187","isVote":1,"tweetType":1,"viewCount":447,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9099575983,"gmtCreate":1643400522440,"gmtModify":1676533816026,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/DIDI\">$DiDi Global Inc.(DIDI)$</a>ddrop until no value","listText":"<a href=\"https://ttm.financial/S/DIDI\">$DiDi Global Inc.(DIDI)$</a>ddrop until no value","text":"$DiDi Global Inc.(DIDI)$ddrop until no value","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":17,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9099575983","isVote":1,"tweetType":1,"viewCount":1043,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":374255803,"gmtCreate":1619450651102,"gmtModify":1704724150743,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SENS\">$Senseonics(SENS)$</a>recovering","listText":"<a href=\"https://laohu8.com/S/SENS\">$Senseonics(SENS)$</a>recovering","text":"$Senseonics(SENS)$recovering","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":1,"link":"https://ttm.financial/post/374255803","isVote":1,"tweetType":1,"viewCount":467,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163669792,"gmtCreate":1623883347216,"gmtModify":1703822205882,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CLNE\">$Clean Energy Fuels(CLNE)$</a>hhold or sell","listText":"<a href=\"https://laohu8.com/S/CLNE\">$Clean Energy Fuels(CLNE)$</a>hhold or sell","text":"$Clean Energy Fuels(CLNE)$hhold or sell","images":[{"img":"https://static.tigerbbs.com/a7e34fa99612c8d92e99de88fb706319","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":7,"repostSize":0,"link":"https://ttm.financial/post/163669792","isVote":1,"tweetType":1,"viewCount":771,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9036359884,"gmtCreate":1646996487894,"gmtModify":1676534185585,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/DIDI\">$DiDi Global Inc.(DIDI)$</a>ddie drop like waterfall","listText":"<a href=\"https://ttm.financial/S/DIDI\">$DiDi Global Inc.(DIDI)$</a>ddie drop like waterfall","text":"$DiDi Global Inc.(DIDI)$ddie drop like waterfall","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":14,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9036359884","isVote":1,"tweetType":1,"viewCount":1018,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091126120,"gmtCreate":1643810511360,"gmtModify":1676533858535,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":14,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091126120","repostId":"860103463","repostType":1,"repost":{"id":860103463,"gmtCreate":1632142934652,"gmtModify":1676530709270,"author":{"id":"3586061751257522","authorId":"3586061751257522","name":"SlowIncome","avatar":"https://static.tigerbbs.com/8f58da85f59ba0a3ddf93647be45c630","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586061751257522","authorIdStr":"3586061751257522"},"themes":[],"htmlText":"(20/09)Today's pre-market GAINERS:<a href=\"https://laohu8.com/S/ZIVO\">$Zivo Bioscience, Inc.(ZIVO)$</a><a href=\"https://laohu8.com/S/EDSA\">$Stellar Biotechnologies(EDSA)$</a><a href=\"https://laohu8.com/S/VSTM\">$Verastem(VSTM)$</a><a href=\"https://laohu8.com/S/LVTX\">$LAVA Therapeutics N.V.(LVTX)$</a><a href=\"https://laohu8.com/S/SYBX\">$Synlogic, Inc.(SYBX)$</a>Please like and follow for daily updates&nbsp;","listText":"(20/09)Today's pre-market GAINERS:<a href=\"https://laohu8.com/S/ZIVO\">$Zivo Bioscience, Inc.(ZIVO)$</a><a href=\"https://laohu8.com/S/EDSA\">$Stellar Biotechnologies(EDSA)$</a><a href=\"https://laohu8.com/S/VSTM\">$Verastem(VSTM)$</a><a href=\"https://laohu8.com/S/LVTX\">$LAVA Therapeutics N.V.(LVTX)$</a><a href=\"https://laohu8.com/S/SYBX\">$Synlogic, Inc.(SYBX)$</a>Please like and follow for daily updates&nbsp;","text":"(20/09)Today's pre-market GAINERS:$Zivo Bioscience, Inc.(ZIVO)$$Stellar Biotechnologies(EDSA)$$Verastem(VSTM)$$LAVA Therapeutics N.V.(LVTX)$$Synlogic, Inc.(SYBX)$Please like and follow for daily updates","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860103463","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":737,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":109739630,"gmtCreate":1619723932420,"gmtModify":1704271346856,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>India stock keep as blue chip","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>India stock keep as blue chip","text":"$Histogenics(OCGN)$India stock keep as blue chip","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/109739630","isVote":1,"tweetType":1,"viewCount":799,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9025664167,"gmtCreate":1653688983159,"gmtModify":1676535325498,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9025664167","repostId":"9089221197","repostType":1,"repost":{"id":9089221197,"gmtCreate":1649995737382,"gmtModify":1676534625922,"author":{"id":"9000000000000641","authorId":"9000000000000641","name":"CyrilDavy","avatar":"https://static.tigerbbs.com/fd67ba4a6ca5ca66b27af6afcce989dc","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"9000000000000641","authorIdStr":"9000000000000641"},"themes":[],"title":"3 best travel stocks to buy as the industry rebounds","htmlText":"Delta Airlines CEO said that the industry was making a comeback. Travel stocks are expected to benefit during this rebound. Airbnb, TripAdvisor, and Booking offer the best returns. The global travel industry is rebounding as countries reopen their borders and ease restrictions. In a statement on Wednesday, Delta’s CEO said that the company has never seen such demand. This explains why travel companies have done well recently. The ETFMG Travel Tech ETF (AWAY) has risen by 20% from its YTD low. Here are some of the best travel stocks to invest in. Airbnb Airbnb<a href=\"https://laohu8.com/S/ABNB\">$Airbnb, Inc.(ABNB)$</a>&nbsp;is a leading company that provides on-demand vacation rentals services. With a market cap of over $109 billion, the firm is more valuable than Hilton, Marriott, and Wynd","listText":"Delta Airlines CEO said that the industry was making a comeback. Travel stocks are expected to benefit during this rebound. Airbnb, TripAdvisor, and Booking offer the best returns. The global travel industry is rebounding as countries reopen their borders and ease restrictions. In a statement on Wednesday, Delta’s CEO said that the company has never seen such demand. This explains why travel companies have done well recently. The ETFMG Travel Tech ETF (AWAY) has risen by 20% from its YTD low. Here are some of the best travel stocks to invest in. Airbnb Airbnb<a href=\"https://laohu8.com/S/ABNB\">$Airbnb, Inc.(ABNB)$</a>&nbsp;is a leading company that provides on-demand vacation rentals services. With a market cap of over $109 billion, the firm is more valuable than Hilton, Marriott, and Wynd","text":"Delta Airlines CEO said that the industry was making a comeback. Travel stocks are expected to benefit during this rebound. Airbnb, TripAdvisor, and Booking offer the best returns. The global travel industry is rebounding as countries reopen their borders and ease restrictions. In a statement on Wednesday, Delta’s CEO said that the company has never seen such demand. This explains why travel companies have done well recently. The ETFMG Travel Tech ETF (AWAY) has risen by 20% from its YTD low. Here are some of the best travel stocks to invest in. Airbnb Airbnb$Airbnb, Inc.(ABNB)$ is a leading company that provides on-demand vacation rentals services. With a market cap of over $109 billion, the firm is more valuable than Hilton, Marriott, and Wynd","images":[{"img":"https://community-static.tradeup.com/news/5afee681cc917aefacca9aca04d6b1c6","width":"-1","height":"-1"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9089221197","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":474,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158742148,"gmtCreate":1625184054784,"gmtModify":1703737764859,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/KOSS\">$Koss(KOSS)$</a>ppls like","listText":"<a href=\"https://laohu8.com/S/KOSS\">$Koss(KOSS)$</a>ppls like","text":"$Koss(KOSS)$ppls like","images":[{"img":"https://static.tigerbbs.com/32e03fcd152cbab313a32cc93332a0b1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/158742148","isVote":1,"tweetType":1,"viewCount":349,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":103304024,"gmtCreate":1619746102768,"gmtModify":1704271744059,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/103304024","repostId":"1188611661","repostType":4,"repost":{"id":"1188611661","kind":"news","pubTimestamp":1619734487,"share":"https://ttm.financial/m/news/1188611661?lang=&edition=fundamental","pubTime":"2021-04-30 06:14","market":"us","language":"en","title":"Amazon sales surge 44% as it smashes earnings expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=1188611661","media":"CNBC","summary":"Amazon released first-quarter results on Thursday that trounced analysts’ expectations.\nThe company ","content":"<ul>\n <li>Amazon released first-quarter results on Thursday that trounced analysts’ expectations.</li>\n <li>The company confirmed that this year’s Prime Day will take place in June, which will likely help year over year comparisons for revenue in the second quarter.</li>\n</ul>\n<p>Amazonshares climbed more than 3.5% in extended trading Thursday after the company&nbsp;released&nbsp;its first-quarter earnings, beating Wall Street’s expectations for earnings and revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/798d7f0536203d2ae33b543f4dabf204\" tg-width=\"1281\" tg-height=\"591\"></p>\n<p>Here’s how the e-commerce giant fared, relative to analyst estimates compiled by Refinitiv:</p>\n<ul>\n <li><b>Earnings:</b>$15.79 per share vs. $9.54 per share expected</li>\n <li><b>Revenue:</b>$108.52 billion vs. $104.47 billion expected</li>\n</ul>\n<p>Few companies have benefited from the pandemic-fueled surge of online shoppingas much as Amazon. Its first-quarter results showed the company’s business continues to be buoyed by the pandemic, with sales soaring 44% year-over-year to $108.5 billion.</p>\n<p>Amazon’s guidance for the second quarter implies that it expects the momentum to continue, which should help allay investor fears that business could slow in a post-pandemic environment. The company expects to post revenue between $110 billion and $116 billion, surpassing Wall Street’s projection $108.6 billion.</p>\n<p>Crucially, Amazon confirmed in its guidance that this year’s Prime Day will take place in June, which will likely help year-over-year comparisons for revenue in the second quarter. Typically, Amazon’s annual, two-day discount bonanza takes place in July, but the company postponed the event to October last year amid pandemic-related uncertainty.</p>\n<p>When asked about the Prime Day timing, CFO Brian Olsavsky said on a call with investors: “In many areas, July is vacation month, so it might be better for customers, sellers and vendors to experiment with a different time period. We believe that it might be better timing later in [the second quarter], so that’s what we’re testing this year.”</p>\n<p>Outside of its core retail segment, Amazon’s cloud-computing and advertising businesses continue to boom. Amazon Web Servicessawnet sales of $13.5 billion during the quarter, up 32% year over year. Amazon doesn’t disclose advertising sales, but it’s included in the company’s “Other” category, which saw its revenues grow 77% year over year to $6.9 billion.</p>\n<p>Amazon CEO Jeff Bezos also gave a rare glimpse into how the company’s streaming business has fared during the pandemic, as stuck-at-home consumers relied on online entertainment to keep busy. “As Prime Video turns 10, over 175 million Prime members have streamed shows and movies in the past year, and streaming hours are up more than 70% year over year,” he said.</p>\n<p>Amazon’s streaming service, Prime Video, is a key offering of the company’s Prime subscription service, which costs $119 a year and includes a range of other benefits like free, two-day shipping. Bezos disclosed earlier this month that the company now has 200 million Prime subscribers, 50 million more than it had at the start of 2020.</p>\n<p>Physical stores revenue, which includes Whole Foods Market and other brick-and-mortar offerings like Amazon Books, continued to fall. Sales slumped 16% to $3.9 billion. The category excludes online delivery, Olsavsky said.</p>\n<p>During the quarter, Amazon’s sales grew faster internationally than they did in North America. International revenue surged 60% year over year, more than any other segment, while North America revenue climbed 40%.</p>\n<p>As expected, Amazon will incur fewer costs this year related to coronavirus safety measures. Operating income is forecast to be between $4.5 billion and $8 billion in the second quarter, assuming $1.5 billion of costs related to Covid-19. That’s in line with what Amazon executives predicted last quarter.</p>\n<p>AmazonsaidWednesday it would spend more than $1 billion on raising wages for over half a million of its U.S. operations workers. On a call with reporters, Olsavsky said it decided to move up the pay increase from the fall to this spring as volumes remain just as strong as they were at the beginning of the pandemic.</p>\n<p>Olsavsky declined to comment on Amazon’s CEO transition plans, which will come into play once Bezossteps down in the third quarter. Bezos will turn the helm over to AWS CEO Andy Jassy and assume the role of executive chairman of Amazon’s board.</p>","source":"lsy1609915699154","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon sales surge 44% as it smashes earnings expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon sales surge 44% as it smashes earnings expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 06:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/29/amazon-amzn-earnings-q1-2021.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amazon released first-quarter results on Thursday that trounced analysts’ expectations.\nThe company confirmed that this year’s Prime Day will take place in June, which will likely help year over year ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/29/amazon-amzn-earnings-q1-2021.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"source_url":"https://www.cnbc.com/2021/04/29/amazon-amzn-earnings-q1-2021.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188611661","content_text":"Amazon released first-quarter results on Thursday that trounced analysts’ expectations.\nThe company confirmed that this year’s Prime Day will take place in June, which will likely help year over year comparisons for revenue in the second quarter.\n\nAmazonshares climbed more than 3.5% in extended trading Thursday after the company released its first-quarter earnings, beating Wall Street’s expectations for earnings and revenue.\n\nHere’s how the e-commerce giant fared, relative to analyst estimates compiled by Refinitiv:\n\nEarnings:$15.79 per share vs. $9.54 per share expected\nRevenue:$108.52 billion vs. $104.47 billion expected\n\nFew companies have benefited from the pandemic-fueled surge of online shoppingas much as Amazon. Its first-quarter results showed the company’s business continues to be buoyed by the pandemic, with sales soaring 44% year-over-year to $108.5 billion.\nAmazon’s guidance for the second quarter implies that it expects the momentum to continue, which should help allay investor fears that business could slow in a post-pandemic environment. The company expects to post revenue between $110 billion and $116 billion, surpassing Wall Street’s projection $108.6 billion.\nCrucially, Amazon confirmed in its guidance that this year’s Prime Day will take place in June, which will likely help year-over-year comparisons for revenue in the second quarter. Typically, Amazon’s annual, two-day discount bonanza takes place in July, but the company postponed the event to October last year amid pandemic-related uncertainty.\nWhen asked about the Prime Day timing, CFO Brian Olsavsky said on a call with investors: “In many areas, July is vacation month, so it might be better for customers, sellers and vendors to experiment with a different time period. We believe that it might be better timing later in [the second quarter], so that’s what we’re testing this year.”\nOutside of its core retail segment, Amazon’s cloud-computing and advertising businesses continue to boom. Amazon Web Servicessawnet sales of $13.5 billion during the quarter, up 32% year over year. Amazon doesn’t disclose advertising sales, but it’s included in the company’s “Other” category, which saw its revenues grow 77% year over year to $6.9 billion.\nAmazon CEO Jeff Bezos also gave a rare glimpse into how the company’s streaming business has fared during the pandemic, as stuck-at-home consumers relied on online entertainment to keep busy. “As Prime Video turns 10, over 175 million Prime members have streamed shows and movies in the past year, and streaming hours are up more than 70% year over year,” he said.\nAmazon’s streaming service, Prime Video, is a key offering of the company’s Prime subscription service, which costs $119 a year and includes a range of other benefits like free, two-day shipping. Bezos disclosed earlier this month that the company now has 200 million Prime subscribers, 50 million more than it had at the start of 2020.\nPhysical stores revenue, which includes Whole Foods Market and other brick-and-mortar offerings like Amazon Books, continued to fall. Sales slumped 16% to $3.9 billion. The category excludes online delivery, Olsavsky said.\nDuring the quarter, Amazon’s sales grew faster internationally than they did in North America. International revenue surged 60% year over year, more than any other segment, while North America revenue climbed 40%.\nAs expected, Amazon will incur fewer costs this year related to coronavirus safety measures. Operating income is forecast to be between $4.5 billion and $8 billion in the second quarter, assuming $1.5 billion of costs related to Covid-19. That’s in line with what Amazon executives predicted last quarter.\nAmazonsaidWednesday it would spend more than $1 billion on raising wages for over half a million of its U.S. operations workers. On a call with reporters, Olsavsky said it decided to move up the pay increase from the fall to this spring as volumes remain just as strong as they were at the beginning of the pandemic.\nOlsavsky declined to comment on Amazon’s CEO transition plans, which will come into play once Bezossteps down in the third quarter. Bezos will turn the helm over to AWS CEO Andy Jassy and assume the role of executive chairman of Amazon’s board.","news_type":1},"isVote":1,"tweetType":1,"viewCount":60,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811339056,"gmtCreate":1630288360175,"gmtModify":1676530257681,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/S51.SI\">$SEMBCORP MARINE LTD(S51.SI)$</a>up","listText":"<a href=\"https://laohu8.com/S/S51.SI\">$SEMBCORP MARINE LTD(S51.SI)$</a>up","text":"$SEMBCORP MARINE LTD(S51.SI)$up","images":[{"img":"https://static.tigerbbs.com/470522b5d856be31331019dda2424171","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/811339056","isVote":1,"tweetType":1,"viewCount":408,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575290973507485","authorId":"3575290973507485","name":"Rookie22","avatar":"https://static.tigerbbs.com/c6852efd5f87d9ecf7965e213c38ac97","crmLevel":4,"crmLevelSwitch":1,"idStr":"3575290973507485","authorIdStr":"3575290973507485"},"content":"Good luck","text":"Good luck","html":"Good luck"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":198106490,"gmtCreate":1620943322510,"gmtModify":1704350729493,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"Diomond hand&nbsp;","listText":"Diomond hand&nbsp;","text":"Diomond hand","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/198106490","repostId":"1118899332","repostType":4,"repost":{"id":"1118899332","kind":"news","pubTimestamp":1620918983,"share":"https://ttm.financial/m/news/1118899332?lang=&edition=fundamental","pubTime":"2021-05-13 23:16","market":"us","language":"en","title":"Ocugen Has a Longer Road To Paying off Than People Think","url":"https://stock-news.laohu8.com/highlight/detail?id=1118899332","media":"InvestorPlace","summary":"Good news from Ocugen has been met with a wave of selling in OCGN stock.\n\nI’ve long been skeptical t","content":"<blockquote>\n <b>Good news from Ocugen has been met with a wave of selling in OCGN stock.</b>\n</blockquote>\n<p>I’ve long been skeptical toward<b>Ocugen</b>(NASDAQ:<b><u>OCGN</u></b>) stock. To some degree, I still am.</p>\n<p>OCGN is pushed as a vaccine play, thanks to its partnership with India’s<b>Bharat Biotech</b>, but some investors miss the fact that the partnership is skewed sharply in Bharat’s favor.</p>\n<p>Ocguen only has rights to distribution in the U.S. It must do all the heavy lifting (financially and operationally) to get Bharat’s Covaxin to market. In return, the company receives just45% of any profits.</p>\n<p>So the idea that OCGN stock is the next<b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>) is quite a stretch. The geographical limitations on the Covaxin license, the past failures in the legacy ocular pipeline, and the profit-sharing agreement leave OCGN at a seeming disadvantage to even the likes of<b>Inovio</b>(NASDAQ:<b><u>INO</u></b>) or<b>Sorrento Therapeutics</b>(NASDAQ:<b><u>SRNE</u></b>).</p>\n<p>The push/pull in OCGN stock reflects these two facts. When Bharat released positive data last month, OCGN soared. It’s since dropped 41% in a matter of days.</p>\n<p>After this most recent fade, however, OCGN does look at least intriguing, even to this skeptic.</p>\n<p>There’s still a lot of work to do, certainly. But Ocugen has the cash and the product. If it can execute, there’s potential upside, even given the constraints of the Bharat deal.</p>\n<p><b>Good News Gets Punished?</b></p>\n<p>I can certainly see how the trading in OCGN over the past few months, and few weeks, would be confusing.</p>\n<p>After all, it seems like Ocugen has delivered mostly good news over that stretch. Data from Bharat on Covaxin gets more detailed and seemingly more positive.</p>\n<p>The second interim results released in April showed100% protection against hospitalization. OCGN soared on that news. Early this month, Bharat showedeffectiveness against the key variantsthat have alarmed scientists of late.</p>\n<p>OCGN actually trades below where it did in early February, though, after the stock tripled following an equity offeringpriced above the market. It will open today at around $8.60.</p>\n<p>Now, comparing OCGN to past peaks has an obvious problem: the stock has seen bubbly trading both in February and the second half of April. Some level of correction was needed in both instances.</p>\n<p>That said, there is a case that the most recent selling has gone a little too far (and indeed shares have found a temporary bottom at the moment). With OCGN approaching $9, the math here can work.</p>\n<p><b>The Math for OCGN Stock</b></p>\n<p>On March 31, Ocugen had $45 million in cash, and 188.2 million shares outstanding. A $100 million equity offeringpriced at $10followed in April.</p>\n<p>Ocugen should close Q2 with about $135 million in cash, assuming its burn rate accelerates as it builds out the infrastructure for Covaxin. That’s probably, though not definitely, enough to get the vaccine to market. Substantial dilution thus seems unlikely.</p>\n<p>Ocugen has a fully diluted market capitalization of nearly $1.8 billion. (That figure includes about 10 million options and warrants outstanding at March 31.)</p>\n<p>So there’s a simplistic question to ask about OCGN stock: can the company generate $2 billion in profit off Covaxin?</p>\n<p><b>Looking to Moderna</b></p>\n<p>That’s likely the minimum required to see any upside here. It’s difficult to assign any material value to the company’s owned pipeline, given the company had a market capitalization below $50 million before the Bharat deal was signed.</p>\n<p>After all, $2 billion is a reasonably high bar. Again, Ocugen only gets 45% of the profits, so Covaxin must generate $4.5 billion or so in earnings.</p>\n<p>We can see from Moderna earnings what the profit profile might look like. Treating previously produced inventory at cost, Moderna’sgross margins were 78%in the first quarter.</p>\n<p>Just to get to $4.5 billion in gross profit, then, Covaxin needs to generate nearly $6 billion in revenue.</p>\n<p>At Moderna’s $19 per dose price, we’re looking at about 300 million doses even before operating expenses. Add in those expenses (it’s tough to estimate, but a few hundred million seems in the ballpark) and Covaxin perhaps needs to move something in the range of 350 million doses.</p>\n<p>Can Covaxin hit that bogey? It does seem tough.</p>\n<p>Moderna is guiding for 200 million to 250 million doses just in the second quarter, but much of that supply is going to international markets.</p>\n<p>For OCGN stock to rise from here, Covaxin probably needs to be one of the most commonly used vaccines domestically, while competing not only with Moderna, but<b>Pfizer</b>(NYSE:<b><u>PFE</u></b>),<b>Johnson &amp; Johnson</b>(NYSE:<b><u>JNJ</u></b>) and presumably others.</p>\n<p>That’s the bet when it comes to OCGN. Honestly, it’s not a bet I’m terribly interested in taking. But with OCGN stock pulling back, reasonable investors probably can disagree.</p>\n<p><i>On the date of publication, Vince Martin did not have (either directly or indirectly) any positions in the securities mentioned in this article.</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Has a Longer Road To Paying off Than People Think</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Has a Longer Road To Paying off Than People Think\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-13 23:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/confusing-trading-leaves-ocgn-stock-interesting/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Good news from Ocugen has been met with a wave of selling in OCGN stock.\n\nI’ve long been skeptical towardOcugen(NASDAQ:OCGN) stock. To some degree, I still am.\nOCGN is pushed as a vaccine play, thanks...</p>\n\n<a href=\"https://investorplace.com/2021/05/confusing-trading-leaves-ocgn-stock-interesting/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://investorplace.com/2021/05/confusing-trading-leaves-ocgn-stock-interesting/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118899332","content_text":"Good news from Ocugen has been met with a wave of selling in OCGN stock.\n\nI’ve long been skeptical towardOcugen(NASDAQ:OCGN) stock. To some degree, I still am.\nOCGN is pushed as a vaccine play, thanks to its partnership with India’sBharat Biotech, but some investors miss the fact that the partnership is skewed sharply in Bharat’s favor.\nOcguen only has rights to distribution in the U.S. It must do all the heavy lifting (financially and operationally) to get Bharat’s Covaxin to market. In return, the company receives just45% of any profits.\nSo the idea that OCGN stock is the nextModerna(NASDAQ:MRNA) is quite a stretch. The geographical limitations on the Covaxin license, the past failures in the legacy ocular pipeline, and the profit-sharing agreement leave OCGN at a seeming disadvantage to even the likes ofInovio(NASDAQ:INO) orSorrento Therapeutics(NASDAQ:SRNE).\nThe push/pull in OCGN stock reflects these two facts. When Bharat released positive data last month, OCGN soared. It’s since dropped 41% in a matter of days.\nAfter this most recent fade, however, OCGN does look at least intriguing, even to this skeptic.\nThere’s still a lot of work to do, certainly. But Ocugen has the cash and the product. If it can execute, there’s potential upside, even given the constraints of the Bharat deal.\nGood News Gets Punished?\nI can certainly see how the trading in OCGN over the past few months, and few weeks, would be confusing.\nAfter all, it seems like Ocugen has delivered mostly good news over that stretch. Data from Bharat on Covaxin gets more detailed and seemingly more positive.\nThe second interim results released in April showed100% protection against hospitalization. OCGN soared on that news. Early this month, Bharat showedeffectiveness against the key variantsthat have alarmed scientists of late.\nOCGN actually trades below where it did in early February, though, after the stock tripled following an equity offeringpriced above the market. It will open today at around $8.60.\nNow, comparing OCGN to past peaks has an obvious problem: the stock has seen bubbly trading both in February and the second half of April. Some level of correction was needed in both instances.\nThat said, there is a case that the most recent selling has gone a little too far (and indeed shares have found a temporary bottom at the moment). With OCGN approaching $9, the math here can work.\nThe Math for OCGN Stock\nOn March 31, Ocugen had $45 million in cash, and 188.2 million shares outstanding. A $100 million equity offeringpriced at $10followed in April.\nOcugen should close Q2 with about $135 million in cash, assuming its burn rate accelerates as it builds out the infrastructure for Covaxin. That’s probably, though not definitely, enough to get the vaccine to market. Substantial dilution thus seems unlikely.\nOcugen has a fully diluted market capitalization of nearly $1.8 billion. (That figure includes about 10 million options and warrants outstanding at March 31.)\nSo there’s a simplistic question to ask about OCGN stock: can the company generate $2 billion in profit off Covaxin?\nLooking to Moderna\nThat’s likely the minimum required to see any upside here. It’s difficult to assign any material value to the company’s owned pipeline, given the company had a market capitalization below $50 million before the Bharat deal was signed.\nAfter all, $2 billion is a reasonably high bar. Again, Ocugen only gets 45% of the profits, so Covaxin must generate $4.5 billion or so in earnings.\nWe can see from Moderna earnings what the profit profile might look like. Treating previously produced inventory at cost, Moderna’sgross margins were 78%in the first quarter.\nJust to get to $4.5 billion in gross profit, then, Covaxin needs to generate nearly $6 billion in revenue.\nAt Moderna’s $19 per dose price, we’re looking at about 300 million doses even before operating expenses. Add in those expenses (it’s tough to estimate, but a few hundred million seems in the ballpark) and Covaxin perhaps needs to move something in the range of 350 million doses.\nCan Covaxin hit that bogey? It does seem tough.\nModerna is guiding for 200 million to 250 million doses just in the second quarter, but much of that supply is going to international markets.\nFor OCGN stock to rise from here, Covaxin probably needs to be one of the most commonly used vaccines domestically, while competing not only with Moderna, butPfizer(NYSE:PFE),Johnson & Johnson(NYSE:JNJ) and presumably others.\nThat’s the bet when it comes to OCGN. Honestly, it’s not a bet I’m terribly interested in taking. But with OCGN stock pulling back, reasonable investors probably can disagree.\nOn the date of publication, Vince Martin did not have (either directly or indirectly) any positions in the securities mentioned in this article.","news_type":1},"isVote":1,"tweetType":1,"viewCount":140,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125955361,"gmtCreate":1624643398853,"gmtModify":1703842714586,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MF\">$Missfresh Limited(MF)$</a>Tencent-back","listText":"<a href=\"https://laohu8.com/S/MF\">$Missfresh Limited(MF)$</a>Tencent-back","text":"$Missfresh Limited(MF)$Tencent-back","images":[{"img":"https://static.tigerbbs.com/c7e0a5f8b663f5ec5e9bfbf1839be163","width":"1080","height":"2400"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/125955361","isVote":1,"tweetType":1,"viewCount":238,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3573894403871485","authorId":"3573894403871485","name":"RS69","avatar":"https://community-static.tradeup.com/news/06904efb023e3dbedbee183f7a163224","crmLevel":7,"crmLevelSwitch":1,"idStr":"3573894403871485","authorIdStr":"3573894403871485"},"content":"Break one's hair [cover one's face]","text":"Break one's hair [cover one's face]","html":"Break one's hair [cover one's face]"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":320537169,"gmtCreate":1615143946151,"gmtModify":1704778866986,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/320537169","repostId":"2117639609","repostType":4,"repost":{"id":"2117639609","kind":"news","pubTimestamp":1614957600,"share":"https://ttm.financial/m/news/2117639609?lang=&edition=fundamental","pubTime":"2021-03-05 23:20","market":"us","language":"en","title":"What's the Outlook for Intuitive Surgical?","url":"https://stock-news.laohu8.com/highlight/detail?id=2117639609","media":"Jason Hawthorne","summary":"Competition is heating up, but the company's market leadership remains unchallenged.","content":"<p>After being relegated to science fiction for most of the 20th century, robots have been more visible over the past two decades. Although most real-world applications so far have been industrial, <b>Intuitive</b> <b>Surgical</b> (NASDAQ:ISRG) has been slowly changing that. The company's da Vinci surgical systems only assist trained humans, but they have become synonymous with the term \"robotic surgery.\"</p><p>After so much success, interested investors will want to determine whether the future can be as bright as the past, or if the combination of COVID, regulatory hurdles, and competition will chip away at the dominance this company has established since going public in 2000.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F615724%2Fgettyimages-1218322943.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p>The arms of a surgical robot. Image source: Getty Images.</p><p><b>Managing through COVID-19</b></p><p>Early during the pandemic, when hospitals were stopping elective procedures to dedicate resources to patients with COVID-19, the company's sales tumbled. Year-over-year revenue declined 22% in the second quarter of 2020 on 19% fewer procedures.</p><p>Procedures and revenue rebounded slightly in the following quarter, up 7% and down 4.5%, respectively, compared to 2019. The fourth quarter finally saw year-over-year revenue growth of 4%, but management remained cautious.</p><p>Citing a holiday rise in COVID-19 cases, CEO Gary Guthart pointed to a lag in diagnostic cases at hospitals and weak surgery data spilling over from December into January as an indication that the sales of da Vinci systems would take several quarters to normalize. With fewer cases, utilization of existing machines will remain low, delaying the need to add capacity.</p><p>Although this is definitely a concern, it's a temporary <a href=\"https://laohu8.com/S/AONE\">one</a>. By the end of 2021, orders and installations should be back to normal. System growth has averaged 12% a year over the past decade and 28% for the three years prior to the pandemic. Investors are hoping the return to normal comes sooner rather than later.</p><p><b>A changing regulatory landscape</b></p><p>In recent quarters, management has become much more vocal about a shifting regulatory landscape in the U.S. and Europe, and the requirement for more data than ever before prior to approval. Guthart has said the requirements have stabilized at a level higher than in past years. Although it's a short-term nuisance, this change stands to benefit incumbents like Intuitive over time, because existing systems will sit on the market longer while innovations wait for approval.</p><p>One region where the company has drastically different regulatory experiences is Asia. Guthart has repeatedly cited South Korea as being quick to allow innovative products to market, while China's centrally managed system is more cautious. System sales in the region grew 60% from 2018 to 2019 before falling off during 2020 due to the pandemic. Products launched in China must have a longer history of performance because that country's version of the Food and Drug Administration handles first-generation products very cautiously. Regardless, the company remains excited about its joint venture with Chinese company Fosun Pharma and expects strong, if somewhat turbulent, demand over time.</p><p><b>Defending the moat</b></p><p>One of the risks in China is the launch of companies trying to bring competitive surgical systems to market. This has already happened in South Korea. That country's embrace of innovation is a double-edged sword for Intuitive -- South Korea's first approved surgical robot was made by <b>Meere</b> back in 2017.</p><p>Asia isn't the only region where companies are tired of Intuitive reaping the lion's share of the robotic surgery opportunity. Closer to home, the company faces long-awaited challenges from device makers <b>Medtronic</b> (NYSE:MDT) and <b>Johnson</b> <b>&amp;</b> <b>Johnson</b> (NYSE:JNJ).</p><p>Medtronic made its intentions clear by acquiring spine surgery innovator Mazor Robotics in 2018. It is planning a launch of its Hugo surgical system outside the U.S. to collect data, and expects to submit for an investigational device exemption from the FDA in the next month. That designation would allow the device to be used in a clinical study.</p><p>Johnson &amp; Johnson has a not-so-secret weapon in the battle for the robotic surgery market: the founder of Intuitive Surgical. Dr. Fred Moll, who practically invented the industry when he founded Intuitive in 1995, is chief development officer at the company's devices unit. With his guidance, the healthcare giant plans to commercialize three robotic platforms it gained via acquisition.</p><p>First, the Velys platform is for total knee replacements. This is the type of high-volume, repeatable procedure that is ripe for robotic assistance. But it's a threat to <b>Stryker</b> and <b>Smith</b> <b>&amp;</b> <b>Nephew</b>, not Intuitive.</p><p>Second, the Monarch platform is for a procedure that lets doctors inspect the lungs and air passages. It will eventually be used for lung biopsies, but Intuitive is already staking a claim here with its Ion system. In fact, Intuitive received FDA approval for the procedure in the first quarter of 2019.</p><p>And third, Johnson &amp; Johnson's Ottava general surgery system was introduced in November after much anticipation. The device integrates with an operating table and has six arms, several more than systems currently on the market. The goal is flexibility. If Ottava can perform many types of operations, it will help hospitals avoid buying multiple robots, each with a different purpose. The system is unlikely to come to market before 2024.</p><p><b>Clear skies, with a few clouds on the horizon</b></p><p>Despite some regulatory red tape at home and upstart competition abroad, the path for Intuitive Surgical to continue its decades of growth seems clear. The company is well ahead of the competition with nearly 6,000 surgical systems already installed around the globe, and it will be hard for competitors to replace them. That is especially true as innovation in da Vinci systems, instrumentation, and capability continues to increase both machine utilization and company sales.</p><p>As a shareholder, I'll be watching the regulatory progress of the competing systems. But changes in the approval process have only made it harder for the competition to get a foothold. With no imminent threats for at least the next few years, the shares will stay tucked away in a part of my portfolio as far from the sell button as any I own. For those looking to add the stock to their own portfolios, the recent market volatility may have provided the opportunity they've been waiting for.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's the Outlook for Intuitive Surgical?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's the Outlook for Intuitive Surgical?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-05 23:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/05/whats-the-outlook-for-intuitive-surgical/><strong>Jason Hawthorne</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After being relegated to science fiction for most of the 20th century, robots have been more visible over the past two decades. Although most real-world applications so far have been industrial, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/05/whats-the-outlook-for-intuitive-surgical/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F615724%2Fgettyimages-1218322943.jpg&amp;w=700&amp;op=resize","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/03/05/whats-the-outlook-for-intuitive-surgical/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2117639609","content_text":"After being relegated to science fiction for most of the 20th century, robots have been more visible over the past two decades. Although most real-world applications so far have been industrial, Intuitive Surgical (NASDAQ:ISRG) has been slowly changing that. The company's da Vinci surgical systems only assist trained humans, but they have become synonymous with the term \"robotic surgery.\"After so much success, interested investors will want to determine whether the future can be as bright as the past, or if the combination of COVID, regulatory hurdles, and competition will chip away at the dominance this company has established since going public in 2000.The arms of a surgical robot. Image source: Getty Images.Managing through COVID-19Early during the pandemic, when hospitals were stopping elective procedures to dedicate resources to patients with COVID-19, the company's sales tumbled. Year-over-year revenue declined 22% in the second quarter of 2020 on 19% fewer procedures.Procedures and revenue rebounded slightly in the following quarter, up 7% and down 4.5%, respectively, compared to 2019. The fourth quarter finally saw year-over-year revenue growth of 4%, but management remained cautious.Citing a holiday rise in COVID-19 cases, CEO Gary Guthart pointed to a lag in diagnostic cases at hospitals and weak surgery data spilling over from December into January as an indication that the sales of da Vinci systems would take several quarters to normalize. With fewer cases, utilization of existing machines will remain low, delaying the need to add capacity.Although this is definitely a concern, it's a temporary one. By the end of 2021, orders and installations should be back to normal. System growth has averaged 12% a year over the past decade and 28% for the three years prior to the pandemic. Investors are hoping the return to normal comes sooner rather than later.A changing regulatory landscapeIn recent quarters, management has become much more vocal about a shifting regulatory landscape in the U.S. and Europe, and the requirement for more data than ever before prior to approval. Guthart has said the requirements have stabilized at a level higher than in past years. Although it's a short-term nuisance, this change stands to benefit incumbents like Intuitive over time, because existing systems will sit on the market longer while innovations wait for approval.One region where the company has drastically different regulatory experiences is Asia. Guthart has repeatedly cited South Korea as being quick to allow innovative products to market, while China's centrally managed system is more cautious. System sales in the region grew 60% from 2018 to 2019 before falling off during 2020 due to the pandemic. Products launched in China must have a longer history of performance because that country's version of the Food and Drug Administration handles first-generation products very cautiously. Regardless, the company remains excited about its joint venture with Chinese company Fosun Pharma and expects strong, if somewhat turbulent, demand over time.Defending the moatOne of the risks in China is the launch of companies trying to bring competitive surgical systems to market. This has already happened in South Korea. That country's embrace of innovation is a double-edged sword for Intuitive -- South Korea's first approved surgical robot was made by Meere back in 2017.Asia isn't the only region where companies are tired of Intuitive reaping the lion's share of the robotic surgery opportunity. Closer to home, the company faces long-awaited challenges from device makers Medtronic (NYSE:MDT) and Johnson & Johnson (NYSE:JNJ).Medtronic made its intentions clear by acquiring spine surgery innovator Mazor Robotics in 2018. It is planning a launch of its Hugo surgical system outside the U.S. to collect data, and expects to submit for an investigational device exemption from the FDA in the next month. That designation would allow the device to be used in a clinical study.Johnson & Johnson has a not-so-secret weapon in the battle for the robotic surgery market: the founder of Intuitive Surgical. Dr. Fred Moll, who practically invented the industry when he founded Intuitive in 1995, is chief development officer at the company's devices unit. With his guidance, the healthcare giant plans to commercialize three robotic platforms it gained via acquisition.First, the Velys platform is for total knee replacements. This is the type of high-volume, repeatable procedure that is ripe for robotic assistance. But it's a threat to Stryker and Smith & Nephew, not Intuitive.Second, the Monarch platform is for a procedure that lets doctors inspect the lungs and air passages. It will eventually be used for lung biopsies, but Intuitive is already staking a claim here with its Ion system. In fact, Intuitive received FDA approval for the procedure in the first quarter of 2019.And third, Johnson & Johnson's Ottava general surgery system was introduced in November after much anticipation. The device integrates with an operating table and has six arms, several more than systems currently on the market. The goal is flexibility. If Ottava can perform many types of operations, it will help hospitals avoid buying multiple robots, each with a different purpose. The system is unlikely to come to market before 2024.Clear skies, with a few clouds on the horizonDespite some regulatory red tape at home and upstart competition abroad, the path for Intuitive Surgical to continue its decades of growth seems clear. The company is well ahead of the competition with nearly 6,000 surgical systems already installed around the globe, and it will be hard for competitors to replace them. That is especially true as innovation in da Vinci systems, instrumentation, and capability continues to increase both machine utilization and company sales.As a shareholder, I'll be watching the regulatory progress of the competing systems. But changes in the approval process have only made it harder for the competition to get a foothold. With no imminent threats for at least the next few years, the shares will stay tucked away in a part of my portfolio as far from the sell button as any I own. For those looking to add the stock to their own portfolios, the recent market volatility may have provided the opportunity they've been waiting for.","news_type":1},"isVote":1,"tweetType":1,"viewCount":52,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":364003602,"gmtCreate":1614783371106,"gmtModify":1704775206681,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"Wait u so long&nbsp;","listText":"Wait u so long&nbsp;","text":"Wait u so long","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/364003602","repostId":"1172714394","repostType":4,"repost":{"id":"1172714394","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614783206,"share":"https://ttm.financial/m/news/1172714394?lang=&edition=fundamental","pubTime":"2021-03-03 22:53","market":"us","language":"en","title":"Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=1172714394","media":"老虎资讯综合","summary":"(March 3) Shares of Histogenics soared 41.0%, after the biopharmaceutical company said its co-develo","content":"<p>(March 3)&nbsp;Shares of <a href=\"https://laohu8.com/S/OCGN\">Histogenics</a> soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.</p><p><img src=\"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8\" tg-width=\"1068\" tg-height=\"517\" referrerpolicy=\"no-referrer\"></p><p>Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.</p><p>\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.</p><p>\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&amp;P 500 has gained 5.6%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-03-03 22:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(March 3)&nbsp;Shares of <a href=\"https://laohu8.com/S/OCGN\">Histogenics</a> soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.</p><p><img src=\"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8\" tg-width=\"1068\" tg-height=\"517\" referrerpolicy=\"no-referrer\"></p><p>Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.</p><p>\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.</p><p>\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&amp;P 500 has gained 5.6%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172714394","content_text":"(March 3) Shares of Histogenics soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&P 500 has gained 5.6%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":97,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150609185,"gmtCreate":1624894525247,"gmtModify":1703847429262,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"power","listText":"power","text":"power","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/150609185","repostId":"150838197","repostType":1,"repost":{"id":150838197,"gmtCreate":1624892123019,"gmtModify":1703847316570,"author":{"id":"3494499094560649","authorId":"3494499094560649","name":"风口浪尖弄潮儿","avatar":"https://static.tigerbbs.com/219409cc1cfcfb61e965bc7466a446e8","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3494499094560649","authorIdStr":"3494499094560649"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics Corporation(OCGN)$</a>立貼爲證！","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics Corporation(OCGN)$</a>立貼爲證！","text":"$Histogenics Corporation(OCGN)$立貼爲證！","images":[{"img":"https://static.tigerbbs.com/ca76715c46ca89b459feea04aa0715e7","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150838197","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":91,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":325509026,"gmtCreate":1615904472865,"gmtModify":1704788275365,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"Crash&nbsp;","listText":"Crash&nbsp;","text":"Crash","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/325509026","repostId":"1121564086","repostType":4,"isVote":1,"tweetType":1,"viewCount":108,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804966673,"gmtCreate":1627916770092,"gmtModify":1703497900260,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INFI\">$Infinity Pharmaceuticals(INFI)$</a>uup.up","listText":"<a href=\"https://laohu8.com/S/INFI\">$Infinity Pharmaceuticals(INFI)$</a>uup.up","text":"$Infinity Pharmaceuticals(INFI)$uup.up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804966673","isVote":1,"tweetType":1,"viewCount":163,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123787649,"gmtCreate":1624439450781,"gmtModify":1703836722215,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TRCH\">$Torchlight Energy Resources(TRCH)$</a>heart attract pump.and dump","listText":"<a href=\"https://laohu8.com/S/TRCH\">$Torchlight Energy Resources(TRCH)$</a>heart attract pump.and dump","text":"$Torchlight Energy Resources(TRCH)$heart attract pump.and dump","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/123787649","isVote":1,"tweetType":1,"viewCount":143,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":137166825,"gmtCreate":1622330600567,"gmtModify":1704182977291,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564546889826365","authorIdStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WTER\">$Alkaline Water Company Inc. (The)(WTER)$</a>Hold blue chip","listText":"<a href=\"https://laohu8.com/S/WTER\">$Alkaline Water Company Inc. (The)(WTER)$</a>Hold blue chip","text":"$Alkaline Water Company Inc. (The)(WTER)$Hold blue chip","images":[{"img":"https://static.tigerbbs.com/2ca2c30a032158ed80f52a2ac5a1a8fa","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/137166825","isVote":1,"tweetType":1,"viewCount":271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}